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Abstract
Background: Aging is marked by a progressive rise in chronic diseases with an impact on social and healthcare
costs. Physical activity (PA) may soothe the inconveniences related to chronic diseases, has positive effects on the
quality of life and biological rhythms, and can prevent the decline in motor functions and the consequent falls,
which are associated with early death and disability in older adults.
Methods: We randomized 120 over-65 males and females into groups of similar size and timing and will give each
either moderate physical activity or cultural and recreational activities. Being younger than 65 years, inability to
participate in physical activity for any medical reason, and involvement in a massive program of physical exercise
are the exclusion criteria. The primary outcome measures are: quality of life, walking speed, and postural sway.
Participants are tested at baseline, post-treatment, and 6-month (24 weeks) and 12-month (48 weeks) follow-ups.
Discussion: This study aims at improving the quality of life, wellness, and cognitive functioning in the elderly
through a low-cost affordable program of moderate physical activity. Given the growing aging of the world
population and the social and economic burden of disability in the elderly, our results might have a major impact
on future practices.
Trial registration: ClinicalTrials.gov NCT03858114. Registered on 28 February 2019.
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Background
Aging is marked by the rise of chronic diseases with an
impact on social and healthcare costs [1]. The European
Union has indicated research on active aging as a prior-
ity [2].
Physical activity (PA) limits disability related to
chronic diseases and has positive effects on the quality
of life and biological rhythms [3], and it also prevents
the decline in motor functions which helps to prevent
falls associated with early death and disability in older
adults [4]. PA improves immune responses in old age
impacting on metabolic disorders, including diabetes [5];
it lowers cognitive and memory decline [6] and acts in
the early stages of depression and in “dysfunctional atti-
tudes” linked to non-acceptance of the limitations im-
posed by age [7]. Prevention of disability attributable to
minor psychological distress can contrast the use of anti-
depressants, thus sparing side effects and metabolic dis-
orders [4].
To date, most studies on the effectiveness of PA proto-
cols in the elderly were based on trials conducted on
small samples, rarely with randomized control designs
and still with contradictory indications on timing and
optimal method of administration (even though both an-
aerobic and aerobic activities seem to be useful). While
the use of subjective/non-instrumental evaluations in the
assessment of motor function outcomes is widespread,
the amount of available data from dedicated laboratory
equipment—able to provide reliable measures of gait
and balance—is limited [8]. Animal studies have shown
that PA may influence brain functions through altered
blood flow, reduce age-related neuronal loss, and stimu-
late de-novo synthesis of neurons. These mechanisms
might be based on increases in growth factors, neuro-
peptides, and endorphins [7]. Studies in animals have re-
cently focused on the insulin-like growth factor-1 (IGF-
1), which was found upregulated in the brain and the
periphery after PA [9]. There is evidence that PA can
positively influence the quality of life in the elderly [10],
and can improve as well symptoms of depression [11],
frequently observed in old people. There is also evidence
that acute intense exercise can increase CD4+ and
CD8+ T lymphocytes in senescent naïve memory and
promote markers of cellular aspects of the immune sys-
tem in elderly subjects [12]. However, most studies have
involved small samples, are based on an acute bout of
exercise, and often lack adequate follow-up, and they do
not generally provide clarifications as to whether PA can
contrast immunosenescence, i.e., the progressive dys-
function of the immune system in the elderly that leads
to increased susceptibility to infections and autoimmune
disease.
This study set up to investigate (a) whether a moderate
activity can be as effective as intense activity in older
people. The available studies did not provide an inter-
vention model based on moderate activity, even though
this could be the only option viable for the elderly with
some medical conditions; (b) the mutual influence of the
different variables involved through complex multidis-
ciplinary perspectives (which has been rarely done so
far).
We have pioneered the clinical trials and systematic
reviews on this topic [3, 13]. The multidisciplinary pro-
ject we propose is an opportunity to address the above-
mentioned issues and to gain further knowledge in the
field of active aging. In particular, this study aims at
measuring—through a randomized controlled trial—
whether an intervention based on moderate PA can im-
prove quality of life (QoL) and motor skills of the elderly
living in the community (primary outcomes). The sec-
ondary objectives are to measure whether physical activ-
ity improves (1) cognitive performance, (2) perception of
pain, (3) biological rhythms and immune response linked
to metabolic control, (4) community assets (settings,
mobility safety, social cohesion), and (5) growth factors
and neurotransmitters in the periphery similarly to out-
comes in animal studies. The study will also allow inves-
tigating the correlation between psychological/motor
improvement and the biological markers. The trial will
be followed by a 48-week follow-up to investigate
whether and to what extent can PA prevent disability
and depressive disorders.
Methods
This is a 12-week randomized controlled trial (RCT)
with subsequent 48-week (circa 12 months) follow-up.
Study design
The study has a longitudinal, two-arm design with par-
ticipants assigned by randomization to either an active
interventional protocol based on physical activity or to a
control condition based on cultural and recreational ac-
tivities focused on education to wellness, cooking, and
the history of local culture. Superiority of the interven-
tion group over the control condition is expected in the
main outcomes. All participants will be assessed in the
pre-treatment period, at the end of the treatment, and at
6 and 12months after the end of the treatment. The
pre-treatment phase consists in a 2-week non-
intervention period during which the participants will be
assessed about their physical, medical, and psychological
status and will receive information about the study so as
to get a fully-disclosed informed consent to participate.
After inclusion in the study, the participants will receive
a 12-week intervention based on either the active condi-
tion or the control condition. All interventions will be
supervised by staff trained on health issues. After the 12-
week intervention, the participants will be assessed to
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ascertain their physical, medical, and psychological sta-
tus, and they will be also investigated about potential is-
sues arisen during the intervention and their global
satisfaction with the program. The protocol has been
prepared according to the Standard Protocol Items: Rec-
ommendations for Interventional Trials (SPIRIT) Check-
list ([14] see appendix).
Participants
The target population includes elderly people living at
home and recruited through public notices. Age range is
as follows: 65 years old and older of both genders. All
participants are expected to hold a medical certificate
for non-competitive physical activity. Exclusion criteria
are as follows: age ≤ 65, BMI > 35, unsuitability for mod-
erate physical activity due to any medical condition, life-
time history of psychosis and/or mania, a certified
organic brain disease, and already involved in a program
of physical exercise at a level equal or higher than 70%
of the expected PA level of the intervention study.
Measures
The following self-report questionnaires will be used:
Short Form Health Survey-12 items (SF-12), as a meas-
ure of quality of life (QoL) [15]; Brief Social Rhythms
Scale (BSRS), a 10-item measure of the regulation of bio-
logical rhythms [16]; International Physical Activity
Questionnaire (IPAQ), a 9-item questionnaire aimed at
measuring the nature and quantity of physical activity in
the past 7 days [17]; and Patient Health Questionnaire-9
items (PHQ-9), a self-administered interview that taps
into the nine DSM-IV-TR (Diagnostic and Statistical
Manual of Mental Disorders-Fourth Edition; Text Revi-
sion) criteria for major depression [18]. The cognitive
status of the participants will be measured with the
Addenbrooke’s Cognitive Examination (ACE), a short
cognitive test (about 15 min for administration), which
evaluates five cognitive areas: attention/orientation,
memory, verbal fluency, language, visual-spatial skills
[19]. The Sickness Impact Profile-Roland Scale (SIP-RS)
for chronic pain will be used as a measure of chronic
pain and its impact on everyday life [20]; the Numeric
Pain Rating Scale (NPRS), a visual analog scale on which
individuals rate their pain on an eleven-point numerical
scale, will be used to obtain an estimate of the current
level of pain [21].
Physiological testing
For all participants, standard anthropometric measures
will be acquired: height in meter, weight in kilograms,
and waist circumference in centimeters.
Gait analysis, baropodometry, and stabilometry and
sit-to-stand (STS) will be used to measure the primary
outcomes in relation to PA. Spatiotemporal parameters
of gait will be assessed using a validated wireless inertial
sensing device. The collected data, transmitted via Blue-
tooth, will allow obtaining a set of gait parameters: stride
length, gait speed, gait cycle duration, stance and swing
duration, and double support duration. Balance abilities
will be assessed through posture. The following mea-
sures will be calculated and analyzed: sway area, center
of pressure (CoP) path length, CoP maximum displace-
ment, CoP velocities in anterior–posterior (AP), and
medial–lateral (ML) directions [22].
Usual functional mobility will be estimated with the
Timed-Up-and-Go (TUG) test, one of the most used
measures of mobility, balance, walking ability, and fall
risk in older adults. The participant is required to get up
from a chair, walk 3 m, go around an obstacle, come
back, rotate 180°, and sit down [23]. The TUG summa-
rizes the skills related to walking, equilibrium, coordin-
ation, and strength of the lower limbs and is typically
assessed in terms of time necessary for its execution. In
this study, participants will perform an instrumental ver-
sion through the use of a wearable inertial sensor ap-
plied in the lumbar region at the height of the L2
vertebra. This allows for more detailed data on each of
the individual sub-phases.
Laboratory tests will include the following: measure-
ment of glycaemia, total cholesterol, high-density lipo-
protein (HDL) cholesterol, triglycerides, melatonin and
insulin-like growth factor-1 (IGF-1) blood levels;
complete blood count, erythrocyte sedimentation rate
(ESR); and C-reactive protein (CRP) levels. As a measure
of immune system efficiency, there will be measure-
ments of immunoglobulin (Ig) G, A, and M (IgG, IgA,
IgM); thymus (T) cells response to mitogens such as
phytohemagglutinin (PHA) and cytometric analysis of
the T helper (Th) subsets, such as Th1, Th2, and Th17
subsets.
Procedure and setting
The project will be carried out at the Department of
Medical Science and Public Health (coordination actions
and data analysis), Laboratory of Movement Analysis at
the Cittadella di Monserrato (medical biomechanical
and neuropsychological assessments and blood essays),
Laboratory of Clinical Biochemistry and Molecular Biol-
ogy of the Azienda Ospedaliero Universitaria (AOU) of
Cagliari (blood analysis), at 4 gyms that participated in
previous joint studies between the University of Cagliari
and CONI (active intervention), and Centro di Riabilita-
zione of the AOU Cagliari (control condition).
Four test points will be set for each participant: base-
line, post-treatment, and 6-month and 12-month follow-
ups. Each test point will include the investigation of
treatment mechanisms and treatment outcome. Each
participant will be assigned to a project coordinator who
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is responsible for the clinical pathways across the trial.
Participants are instructed to report any change in their
treatment regimen to the study coordinator they are
assigned to. During the trial, all participants will con-
tinue their usual treatments and, when they must receive
additional prescriptions, they are allowed to take their
new treatment unless the treatment implies the loss of
eligibility for non-competitive physical activity. In this
case, the participant will be withdrawn from the study
irrespectively from his/her current allocation. Appropri-
ate debriefing will follow the decision to withdraw the
participant from the study.
Baseline testing
The baseline testing will be in separate days: on 1 day,
the participants will be assessed for their physiological
and medical condition, also conducting the laboratory
tests; on a separate day, the participants will be assessed
for their psychological and psychiatric status.
Randomization
Randomization will be conducted at the University of
Cagliari after baseline assessment. Randomization will be
computer-based and concealed. The people who will
conduct the randomization procedure are blind to the
participants’ identities and status and will not receive
any information on the participants. Randomization will
be by blocks of randomized permutations to experimen-
tal treatment with a 1:1 rate; codes will be masked.
Allocation concealment
Random allocation sequence is generated and distributed
in envelopes. The concealment is performed by a mem-
ber of the research team; this person is not a member of
the assessment team nor of the data analysis team.
When a person is enrolled, an envelope is opened and
the allocation is made known to the person doing the
assignment.
Blinding
The participants will be blind about the condition la-
beled as active intervention (PA or cultural and recre-
ational activities). The participants will be informed that
they will be proposed the participation in activities they
can enjoy and which can improve their quality of life as,
for example, taking a guided tour of the historical places
of the town, receiving a short cooking course, taking
part to a low-impact physical activity in a gym, and so
on. Information will be given about the pros and cons of
each activity, without any detail about which activity
could improve their quality of life the most. If someone
asks these details, they will be invited to “just try.”
The medical and psychological examiners will be blind
to whether the participants have been assigned to the
active intervention or the control condition. The project
coordinator will schedule meetings with the participants
before each appointment, to instruct them not to reveal
which treatment they received. In the eventuality that
the participants violate this assignment, at the end of the
trial, each independent assessor will be asked whether
the participant revealed the intervention received; the
answer will be recorded to estimate the percentage of
blinding violation. The trainers involved in the adminis-
tration of the active intervention or of the control condi-
tion will be blind about the psychological status of the
participants. Blinding will be extended to the data ana-
lysis team. Data analysts will be blind to treatment allo-
cation since group belonging will be registered as “group
A” and “group B,” with no description of the nature of
the intervention.
Pre-treatment period
The pre-treatment phase consists of a 2-week non-
intervention period during which the participants will be
assessed about their physical, medical, and psychological
status and will receive information about the study.
Treatment
After signing the informed consent, the enrolled subjects
will be randomly allocated to experimental treatment by
blocks of randomized permutations with a 1:1 rate;
codes will be masked. Participants will be evaluated at
time zero (t0), baseline; t1, week 12, end of the trial; t2,
24 weeks (circa 6 months) after end of trial; and t3, 48
weeks (circa 12 months) after the end. Blood samples
will be conducted at t0 and t1 (3 daily samplings will be
made to check the circadian changes). A questionnaire
about exercise during the previous six weeks will be
done at t0, t2 and t3 (see Table 1 for details; all items
can be found in the protocol).
Post-treatment
Post-treatment testing is expected to start within 2
weeks after the last treatment session. The post-
treatment testing corresponds to the baseline (pre-treat-
ment) testing.
Follow-up testing at 6 months
The 6-month (24 weeks) testing includes both a medical
examination and the psychological testing as in the base-
line (pre-treatment) period. However, no laboratory test
will be conducted.
Follow-up testing at 12months
The 12-month (48 weeks) testing is the same as the 6-
month testing.
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Interventions
A. Physical exercise
The active intervention will consist in 3 sessions per
week. PA was established as 60–84% of the Heart Rate
Reserve (HRR); it will monitored continuously during
activity and transmitted to the fitness professionals by a
telemetry system. The individual HRR for each partici-
pant will be assessed according to the Estimated Max-
imal Heart Rate Formula. Baseline HR will be registered
for all participants as a 3-day mean. PA consists of three
Table 1 Schedule of enrolment, interventions, and assessments
Study period
Time point tx t0 12 weeks t1 t2 t3








Adverse events monitoring ←--------→
Assessment
Medical assessment X X
Anthropometric measurement X X
Demography X
Questionnaires
SF-12 X X X X
BSRS X X X X
IPAQ X X X
PHQ-9 X X X X
SIP-RS X X X X
NPRS X X X X
Cognitive testing












IgG, IgA, IgM X X
PHA test X X
T-helper Th1, Th2, Th17 X X
Abbreviations: ACE, Addenbrooke’s Cognitive Examination; BSRS, Brief Social Rhythms Scale; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Ig,
immunoglobulin; HDL, high-density lipoprotein cholesterol; IGF-1, insulin-like growth factor-1; IPAQ, International Physical Activity Questionnaire; NNT, number
needed to treat; NPRS, Numeric Pain Rating Scale; PHA, phytohemagglutinin; PHQ-9, Patient Health Questionnaire-9 items; SF-12, Short Form Health Survey 12
items; SIP-RS, Sickness Impact Profile-Roland Scale; STS, sit-to-stand; T, thymus; TUG, Timed-Up-and-Go. All items can be found in the protocol
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phases: (1) warm up, 10-min, 60% of HRR; (2) active
phase, 45-min, 60–84% HRR; (3) cool down, 10-min, <
60% HRR. The active phase was designed as a mixture
of aerobic and anaerobic exercises, integrating drills of
“life movements,” strength, and balance.
B. Educational and leisure activities
The control group condition will consist in cultural and
recreational activities focused on education to wellness,
cooking, and the history of local culture headed by an
“animator” (with a degree as rehabilitation educator) in
groups of the same size (n = 15 in each group) and tim-
ing as the active intervention group. The control group
condition is expected to involve participants for the
same amount of time in groups of the same size as the
intervention condition, but without the involvement of
physical activity, in order to provide a comparator that is
devoid of the intended effective stimulus while all the
other effects are taken into account (e.g., sociality,
amusement, bonding, sharing of time, companionship).
Primary outcomes
The primary outcomes are quality of life, walking speed,
and postural sway. All primary outcomes will be aggre-
gated according to their mean and the outcome will be
assessed as a change from the baseline. Table 2 lists the
main characteristics of the primary outcomes according
to their elements as in Saldanha et al. [24].
Recruitment and eligibility
Participants will be recruited through public notices and
referrals by primary health care services. The Italian
Olympic Committee (Comitato Olimpico Nazionale Ita-
liano – CONI) will contribute to the study through sup-
port in recruiting the elderly (through radio ads, TV,
newspapers) and selecting the gyms and the trained staff
to carry out the intervention.
To be eligible for the trial, each participant must pro-
vide a formal referral from a primary physician to the
hospital and a medical certificate of suitability for non-
competitive physical activity. After referral by their pri-
mary physician, the participant is preliminarily assessed
for eligibility. If eligible for inclusion, participants sign
an informed consent form and complete self-report
baseline measures.
Strategies to improve adherence
Participants will be randomly inquired about their satis-
faction with the activities they are involved in. Reasons
for skipping a session will be discussed. After every ses-
sion, the participants will receive a reminder about the
next session by a team member.
Data management and security
Each potential participant is assigned a unique identifi-
cation number at the start of the assessment. The study’s
coordinators and the research team member in charge
of the allocation will know only the pairing between the
identity of the participants and their unique identifica-
tion number. Data are stored according to the hospital’s
regional secure rules. Biological material will be stored
in a research-specific biobank, according to the proce-
dures of the Regional Committee for Medical and Health
Research Ethics. For the analysis, data will be collected
in an Excel pre-form. Double-check will be applied rou-
tinely to assure that data imputation is correct. All data
will be analyzed in an anonymous form and they will be
kept for 5 years after the completion of the trial, then
they will be destroyed.
Ethical issues
Each participant will be followed by a project coordin-
ator who is responsible for the clinical pathways across
the trial. The project coordinator will be responsible for
managing any issue or adverse event that may arise dur-
ing the trial. Since it is enough to ask the participants
what they were doing to identify their experimental/con-
trol status, in case of adverse events, no unblinding pro-
cedure neither a procedure for revealing the participant’s
allocated intervention during the trial has been estab-
lished. At the end of treatment, each patient will receive
clarifications about follow-up testing and will be offered
the opportunity to give feedback on treatment and re-
search participation. If any health issue arises during the
trial, the project coordinator will refer the participant to
the primary physician and, if necessary, will address the
participant to the appropriate medical facility for emer-
gency treatment. In case of the emergence of a health
condition that precludes further participation in the trial,
the participant will be discontinued from trial participa-
tion with full disclosure of the reasons. All participants
Table 2 Elements of the completely specified primary outcomes
Domain Measurement Metric Aggregation Time-point
Quality of life SF-12 Change from baseline Mean At week 12 (end of treatment)
At week 48 (end of follow-up)
Walking speed Gait analysis Change from baseline Mean At week 12 (end of treatment)
Postural sway area Stabilometry Change from baseline Mean At week 12 (end of treatment)
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will be insured through a trusted insurance company
(name omitted for privacy reasons).
The total load of testing and treatment has been de-
signed to be within the limits that participants aged 65
years and older can tolerate on the basis of past pilot
studies done in the same population.
Adverse event reporting and harms
Physical activity may be a source of concern in the eld-
erly. Adverse events may occur also during leisure activ-
ities, e.g., a fall during access to the room where the
educational and leisure activities are held. During the
trial, and thereafter during the follow-up, adverse events
will be continuously collected and assessed at each visit.
Adverse events monitoring will be recorded on an ad
hoc schedule. Each adverse event will be reported in-
cluding details about the type of adverse event, its begin-
ning and end (date and time), its severity (from mild to
severe), whether or not it could have been expected, its
outcome (from completely solved to fatal), and whether
or not it was related to the study (certainly/probably/
possibly/unlikely/cannot say). Expected adverse events
are those that can occur according to the activity (phys-
ical or leisure activity), such as muscle strain or fall. Un-
expected adverse events are the sudden worsening of a
pre-existing minor somatic disorder or cardiovascular
events, such as stroke or heart attack, unrelated to the
activity.
In case of serious adverse events, a written report will
be prepared as per the ethical approval, with details
about the participant and the nature of the event. Both
the Regional Committee for Medical and Health Re-
search Ethics, region of Sardinia, and the participant’s
general practitioner will be notified about any serious
adverse event, whether or not it was judged related to
the study trial.
Participants incurring serious adverse events from
moderate (requiring a relevant change in the treatment)
to severe (requiring hospitalization) will be suspended
from the study. Mild adverse events (requiring minimal
change in the treatment or none at all, or some days of
rest at home) will be not a reason for the termination of
the trial. Data concerning participants that were sus-
pended from the trial because of adverse events will be
entered in the analysis by treatment allocated, as per the
CONSORT statement [25].
Power analysis and statistical analysis
Sample size for expected difference in the primary out-
come was based on pilot trials. Effect size of treatment
on various outcomes, including motor skills, was 0.48
mean of the standard deviation (SD), with 95% CI = 0.10
to 0.85. As for quality of life and mood, we aimed at de-
tecting clinically significant changes induced by
moderate physical exercise. In a recent meta-analysis,
moderate-to-vigorous physical exercise was associated
with a medium effect size of 0.64 (95% CI, 0.27 to 1.01)
in reducing depressive symptoms [26]. Overall, we ex-
pect that the experimental intervention could produce a
change in the exposed group with an effect size of 0.45
SD. We have determined, by a test of difference between
proportions, that a sample of 60 participants per group
is required to achieve 80% power to detect a difference
with a medium effect size h = 0.45, at a two-sided sig-
nificance level of 0.05. It means that at the estimated
power, risk reduction is 0.215, and number needed to
treat (NNT) = 5.
The main outcome measures and expected improve-
ment are the following: SF-12 score (10%), walking speed
(10%), and postural sway area (20%). Differences in the
primary outcomes will be analyzed with a two-tail test
for proportions with the Miettinen exact test. A multiple
logistic regression will be performed to treat the con-
founding factors and control the impact of the con-
founding variables (sex, age, co-morbid condition,
previous exercise activity) on outcomes. Survival ana-
lyses will be carried out using the Kaplan-Meier curve.
Data will be analyzed at the individual level, and cluster-
ing (participants having been exposed to the intervention
in groups) will be not accounted for in the analysis. Ana-
lysis by treatment allocated will be used considering
both primary and secondary outcomes. The analysis by
treatment allocated will include all participants for
which there is data at t0. There will be no interim ana-
lyses planned for efficacy or safety since this is a short
trial with no administered drug. Analyses will be done
with Excel or the Statistical Package for Social Science
(SPSS).
Methods to handle missing data
We do not expect many missing data since the study will
be carried out within just one center and the interven-
tional trial has a short duration (12 weeks). However,
missing data may occur during the follow-up period.
Thus, in the primary analysis, missing data will be re-
placed by “last-observation-carried-forward.” Then, mul-
tiple imputations will be used for sensitivity analyses.
Oversight and monitoring
The coordinating center staff includes psychiatrists, psy-
chologists, occupational therapists, and nurses, who will
be responsible for patient enrollment and the assessment
of psychosocial and exercise outcomes; anesthesiologist,
cardiologists, internists, dermatologists, orthopedic sur-
geons, physiatrists, sport medicine physicians, who will
be in charge of patient safety and clinical outcome as-
sessment; and geneticists, biologists, laboratory staff, re-
searchers, and data analysts responsible for storing and
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measuring biomarkers, collecting data, and compiling
the case report forms and the database. The coordinat-
ing center staff will interlace with the activity of the re-
searchers from the participating center.
The study will have a Steering Committee, a Data
Safety Monitoring Committee, and a Quality Control
Committee. The Steering Committee comprises the
principal investigator, a forensic physician, a dermatolo-
gist, an engineer with expertise in gait analysis, an
anesthesiologist, a statistician, and a psychiatrist, who
also serves as data analyst. The Steering Committee
oversees the advancement of the study, identifies prob-
lems and difficulties, and implements appropriate cor-
rective measures. The Data Safety Monitoring
Committee includes the principal investigator, a nurse,
an occupational therapist, an anesthesiologist, and a car-
diologist. It is in charge of study monitoring until the
end of the follow-up with respect to the study imple-
mentation and progress and of making recommenda-
tions concerning the continuation, modification, or
termination of the trial in relation to unforeseen adverse
events of concern. The Quality Control Committee in-
cludes the principal investigator, a psychologist, a biolo-
gist, and a geneticist and will monitor the study for
efficacy and safety. The Data Safety Monitoring Com-
mittee and the Quality Control Committee are com-
pletely independent from the sponsor that funded the
study.
Dissemination of results
The results of the trial will be disseminated through
communications at international meetings and con-
gresses and by publications in high-impact and, prefera-
bly, open-access international peer-reviewed journals.
Public media will be reached to disseminate the main
findings of the trial, and lectures will be given to health
care practitioners and voluntary organizations.
Discussion
Older adults are a rapidly growing group: 22% world-
wide and 36% of the Italian population will be over 65 in
2050. Older patients often do not receive adequate and
effective help through the current healthcare systems,
and comorbid somatic and psychiatric disorders are
common in this age class of the population causing an
important socioeconomic burden. For these reasons, it is
important to provide low-cost, effective treatment for
minor psychological disorders that may impact on the
somatic health and wellness of elderly. An increase in
quality of life may be pivotal in improving the psycho-
logical and somatic status of the elderly. To date, the
evidence that PA can positively influence the QoL in the
elderly [10] and can improve as well the symptoms of
depression [11] that are frequently observed in old
people, is based on small samples, often without ran-
domized control design and with contradictory indica-
tions on timing and optimal modality of administration.
The positive impact of PA on the immune system in the
elderly is often the result of acute bouts of exercise in
studies that often lack adequate follow-up to investigate
the persistence of these acute effects [12]. It is still un-
known whether the improvement in the quality of life
and immunity is a reflection of an impact on biological
rhythms; it depends on better wellness and reduced de-
pressive dysfunctional attitudes or still is a direct effect
of PA.
This study aims at assessing the effects of moderate
PA on an elderly sample’s QoL, biological rhythms
(sleep/wake; nutrition and daily life activities), depressive
dysfunctional attitudes, static-dynamic balance, cognitive
functioning, and at determining the occurrence, if any,
of adverse events that are possible in elderly people
while performing PA. The study also aims at testing the
relationships of such outcomes with the increase of
melatonin, IGF-1, and immune response in the blood
and to verify the relationships of PA with community as-
sets (settings, mobility safety, social cohesion). The study
design includes a control condition that is not expected
to provide relevant effects on the main outcomes, al-
though by effect of sociality and the formation of social
bonds during the recreational activities, it is still possible
that a fraction of the participants may benefit in terms
of QoL. The effects of the control condition on the
physiological parameters are less likely. In particular, we
expect that the PA intervention, but not the control con-
dition focused on recreational activities, will impact on
the immune system by improving some of the measures
that have been selected to assess its functioning: mea-
surements of IgG, IgA, and IgM; T cells response to mi-
togens such as PHA and cytometric analysis of the Th1,
Th2, and Th17 subsets.
Given the social and economic importance of the issue
of disability in the elderly, our results could have a major
impact on future practices. The main outcomes of the
project are related to the availability of a standardized
model of intervention in the real life, while the second-
ary objectives will provide a set of heuristic hypotheses
in a research field defined as a priority for the next Hori-
zon calls. A general objective of the project is also to in-
crease the multi-disciplinary skills and the attitude to
joint work in a field that is a primary recipient of EU
funding.
The large number of tests and measurements at mul-
tiple time points is the main strength of the study, since
this allows investigation on the moderators and media-
tors of treatment efficacy, a point often neglected in past
studies. Nevertheless, the number of tests may pose a
challenge to the participants, increasing the risk of
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dropout at post-treatment and follow-up. Many ques-
tionnaires also pose the risk of missing data, which is an-
other limitation of the study. Great care will be given to
minimize the risk of dropout and incomplete assessment
by periodic meetings with the assessors and clarifications
to the participants at each test point. It should be noted
the lack of accounting for clustering in the analysis,
which might bring some potential limitations. However,
in this study, the number of clusters is really low, and
accounting for clustering, in this case, might lead to
biased estimates of standard errors [27].
Trial status
The study is registered on ClinicalTrials.gov
(NCT03858114). The Regional Ethical Committee has
approved the study with reference number PG/2018/
15546, approved 25 October 2018. The study opened for
recruitment in March 2019, and we plan to conclude
data collection in June 2020. Protocol version n. 3.2.4;
15 April 2021.
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